BC Innovations | Feb 13, 2018
Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected...
BC Innovations | Oct 24, 2017
Distillery Therapeutics

Neurology

INDICATION: Amyotrophic lateral sclerosis (ALS) Cell culture studies suggest inhibiting HDAC6 could help treat ALS. In ALS patient-derived motor neurons, inhibition of HDAC6 with two tool compounds or antisense oligonucleotide (ASO)-mediated knockdown decreased axon transport...
BC Innovations | Feb 15, 2017
Distillery Therapeutics

Neurology

INDICATION: Nerve damage Studies in mice suggest inhibiting HDAC2 could help treat peripheral nerve damage. In a mouse model of sciatic nerve injury, Schwann cell-specific knockout of HDAC2 increased axonal regrowth and sprouting compared with...
BC Innovations | Jan 30, 2014
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Post-traumatic stress disorder (PTSD) Histone deacetylase 2 (HDAC2) Mouse studies suggest HDAC2 inhibitors could help treat PTSD associated with long-term traumatic...
BC Innovations | Sep 26, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression Histone deacetylase 6 (HDAC6) In vitro and mouse studies suggest inhibiting HDAC6 in the brain could help treat depression. In...
BC Week In Review | Aug 5, 2013
Company News

Acetylon, Array BioPharma, Celgene deal

Celgene paid $100 million up front in exchange for an exclusive option to acquire Acetylon. If Celgene exercises its option, Acetylon will receive at least $500 million in cash up front and Acetylon shareholders would...
BioCentury | Aug 5, 2013
Strategy

Future-proofing MM

Celgene Corp. 's deal with Acetylon Pharmaceuticals Inc. hinges on the expectation that epigenetic therapy combinations will become mainstays of multiple myeloma treatment and gives Celgene first crack at ACY-1215 - the most advanced HDAC6 inhibitor...
BC Extra | Jul 30, 2013
Top Story

Celgene receives option to acquire Acetylon

Celgene Corp. (NASDAQ:CELG) paid $100 million up front in exchange for an exclusive option to acquire Acetylon Pharmaceuticals Inc. (Boston, Mass.). If Celgene exercises its option, Acetylon will receive at least $500 million in cash...
Items per page:
1 - 8 of 8